Abstract HIV-associated neurocognitive disorders (HANDs) continue to be common and are associated with increased morbidity and mortality. However, the underlying mechanisms in the combination antiretroviral therapy (cART) era are not fully understood. Interferon alpha (IFNα) is an antiviral cytokine found to be elevated in the cerebrospinal fluid (CSF) of individuals with advanced HIV-associated dementia in the pre-cART era. In this cross-sectional study, we investigated the association between IFNα and neurocognitive performance in ambulatory HIV-infected individuals with milder impairment. An eight-test neuropsychological battery representing six cognitive domains was administered. Individual scores were adjusted for demographic characteristics, and a composite neuropsychological score (NPT-8) was calculated. IFNα and CSF neurofilament light chain (NFL) levels were measured using enzyme-linked immunosorbent assay (ELISA). There were 15 chronically infected participants with a history of significant immunocompromise (median nadir CD4+ of 49 cells/μl). Most participants were neurocognitively impaired (mean global deficit score of 0.86). CSF IFNα negatively correlated with three individual tests (Trailmaking A, Trailmaking B, and Stroop ColorWord) as well as the composite NPT-8 score (r = −0.67, p = 0.006). These negative correlations persisted in multivariable analyses adjusting for chronic hepatitis B and C. Additionally, CSF IFNα correlated strongly with CSF NFL, a marker of neuronal damage (rho = 0.748, p = 0.0013). These results extend findings from individuals with severe HIV-associated dementia in the pre-cART era and suggest that IFNα may continue to play a role in HAND pathogenesis during the cART era. Further investigation into the role of IFNα is indicated.
Background
HIV-associated neurocognitive disorders (HANDs) continue to be a major problem in the era of combination antiretroviral therapy (cART). Studies in mostly cART-treated populations have shown that HAND is present in 25-50 % of HIV-infected individuals (Heaton et al. 2010; Robertson et al. 2007 ). In addition to being highly prevalent, HAND is associated with multiple adverse clinical outcomes, including decreased quality of life and increased mortality (Tozzi et al. 2003; Vivithanaporn et al. 2010 ).
This work was presented in part as CSF interferon alpha levels inversely correlate with processing and motor speed in HIV-infected subjects with cognitive complaints with and without HIV-associated neurocognitive disorder. Poster Abstract 437, 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, GA, 2013. Yet, the pathogenesis of HAND, particularly in the setting of cART, has not been fully elucidated. A number of soluble biomarkers have been studied and are associated with the presence of HAND. Interestingly, many of these biomarkers appear to represent diverse pathological pathways (neopterin reflecting monocyte activation, neurofilament light chain reflecting neuronal degeneration, and others) (Hagberg et al. 2010; Marcotte et al. 2013; Peterson et al. 2014) . Therefore, more research is needed to identify biomarkers that could contribute to a more comprehensive picture of HAND pathogenesis. Additionally, given that no treatments other than cART have been found to ameliorate HAND (Sacktor et al. 2011 ) (and even with cART the disorder is often not completely eradicated), new therapeutic targets are needed.
Interferon alpha (IFNα) is an antiviral cytokine found to be the only type I interferon that is elevated in the plasma of HIVinfected individuals compared to uninfected controls (Hardy et al. 2013) . IFNα has been shown to have a direct neurotoxic role in animal models as well as in humans. In a murine model of HIVencephalitis, mice develop altered behavior and express increased IFNα in the brain (Sas et al. 2009 ). Blockage of IFNα in the setting of this model has been shown to ameliorate encephalitis (Fritz-French et al. 2014) . In humans, IFNα has been associated with significant neuropsychiatric toxicity when used for the treatment of chronic hepatitis C infection and other diseases (Fritz-French and Tyor 2012) . While found to be undetectable in >90 % of normal individuals (Abbott et al. 1987 ), CSF IFNα levels were shown to be significantly elevated among individuals with HIV-associated dementia in the precART era (Rho et al. 1995) . However, given that HAND during the cART era is mostly composed of milder impairment (Heaton et al. 2010) , further research on the role of IFNα is indicated. Therefore, we sought to measure CSF IFNα in a cohort of predominantly cART experienced individuals to determine its relationship with neurocognitive performance.
Methods
Participants HIV-infected adult outpatients who reported changes in memory were enrolled between March 2011 and November 2011 at the Emory University Center for AIDS Research (CFAR) clinical core site in Atlanta, GA. In order to minimize confounding comorbidities, potential participants were excluded from the study for any of the following: (1) history of any neurologic disease known to effect memory (including stroke, malignancy involving the central nervous system, traumatic brain injury, and AIDS-related opportunistic infection of the central nervous system); (2) ongoing substance use (marijuana use in the last 7 days or cocaine, heroin, methamphetamine, or other non-marijuana illicit drug use in the last 30 days); (3) heavy alcohol consumption in the last 30 days (defined as >7 drinks per week for women and >14 drinks per week for men); or (4) serious mental illness including schizophrenia and bipolar disorder (depression was not excluded if participants were well controlled on treatment). Participants were also screened for hypothyroidism (with serum TSH level), vitamin B12 deficiency (with serum B12 level), and cryptococcal disease if CD4+ T-cell count was <100 cells/μl (with serum cryptococcal antigen) and excluded if any were found to be abnormal. Participants with a history of treated syphilis and a persistently positive rapid plasma reagin (RPR) titer of 1:4 or less were eligible for the study if there was a decrease in RPR of at least fourfold at 6 months after treatment, and there were no neurological symptoms at initial syphilis presentation. Lastly, participants were excluded in the event that severe cognitive symptoms had occurred precipitously in the last 30 days in order for further medical workup to be undertaken.
Neuropsychological testing
The neuropsychological (NP) battery included the HIV dementia scale as well as the following eight tests that are used commonly in studies of cognition during HIV infection (Robertson and Yosief 2014) (Antinori et al. 2007 ). The tests were administered by study staff after intensive training and supervision by an experienced, board certified neuropsychologist (DL). Test scores were adjusted for demographic characteristics using published norms ) that account for age, sex, and race (with the exception of HVLT and Stroop tests, for which adjusted values were not available) to arrive at individual T scores. A composite neuropsychological test score (NPT-8) was then calculated by averaging the eight individual T scores, as performed in other studies of neurocognition in HIV. Global deficit score (GDS), a validated measure of neurocognitive impairment in HIV based on demographically corrected T scores, was also calculated and as per published literature a score of ≥0.5 was indicative of neurocognitive impairment (Carey et al. 2004 ). The study was approved by the Emory University Institutional Review Board, and written consent was obtained from all subjects.
Blood and cerebrospinal fluid evaluations
On the same day of NP testing, paired blood and CSF samples were obtained, processed, and stored at −80°C. Plasma and CSF HIV RNA levels were quantified with the Abbott laboratories Real Time HIV-1 assay (reverse transcriptase polymerase chain reaction) using the Abbott m2000 system. Lowest limit of HIV detection was 40 copies/ml. IFNα levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits (PBL Assay Science, Piscataway NJ, USA) according to the manufacturer's instructions and technicians were blinded to clinical data. All samples and standards were measured in triplicates as picograms/milliliter (pg/ml). CSF neurofilament light chain (NFL), an established marker of neuronal injury (Peterson et al. 2014) , was also measured by ELISA (UmanDiagnostics, Umea, Sweden). The NFL assay is most specific for myelinated axons and has intra-assay coefficients of variation below 10 %. All NFL samples were analyzed as single samples in one round of experiments using one batch of reagents by board-certified laboratory technicians who were blinded to clinical data. Other studies including CD4+ Tlymphocyte counts were performed by the hospital clinical laboratories. In addition to the HIV-infected participant samples, the cerebrospinal fluid samples from four HIVseronegative individuals were included for IFNα testing.
Statistical analyses
Statistical analyses were performed with SAS software (version 9.4, SAS institute, Cary, NC) as well as SAS JMP (version 12.0, SAS institute, Cary, NC). Normality was assessed with the Shapiro-Wilk test. Differences between non-normal groups were calculated with the Wilcoxon rank-sum test. For correlations, non-normal variables were log10 transformed for the Pearson product moment correlation coefficient (r). If log10 transformation did not yield values that met criteria for normality, the Spearman correlation test (rho) was used. Alpha levels were two-tailed, and a p value of <0.05 was considered statistically significant. Analyses with multiple pvalues of <0.05 were corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) procedure. For correlations between IFNα and NP measures that remained statistically significant after FDR, linear regression analysis (analysis of covariance (ANCOVA)) was then used to generate adjusted Pearson correlation coefficients accounting for the presence of chronic hepatitis B or C.
Results
A total of 15 HIV-infected participants were enrolled. Median age (Table 1) was 49 years, 80 % were men, and 73.3 % were African-American. Most subjects had a long history (median 8 years) of HIVand a history of significant immunocompromise (median CD4+ nadir of 49 cells/μl and median current CD4+ of 62 cells/μl). The majority of subjects (60 %) were cART experienced and 20 % were currently on cART with undetectable plasma and CSF HIV RNA < 40 copies/ml. Mean NPT-8 score was 43.7 (standard deviation 9.34) and mean GDS of 0.86 (standard deviation 0.995). Nine of 15 subjects (60 %) met criteria for neurocognitive impairment by GDS ≥0.5 while 4 of 15 (26.7 %) had more severe impairment with GDS ≥1.5. Median CSF IFNα result was 7.86 pg/ml (range 2.62-45.95), and median CSF NFL result was 563 pg/ml (range 293-12,233). CSF IFNα correlated significantly with CSF NFL (rho = 0.748, p = 0.0013). There were two healthy HIV-seronegative controls (one 57-year-old female with CSF IFNα level of 2.14 pg/ml and one 52-year-old female with CSF IFNα 1.19 pg/ml) as well as two HIV-seronegative individuals with Alzheimer's disease (one 64-year-old male with CSF IFNα 5.95 pg/ml and one 73-year-old female with CSF IFNα 3.1 pg/ml). CSF IFNα level was significantly higher (p = 0.012) in the participants with HIV (median 7.86 pg/ml, overall range 2.62-45.95) compared to the participants without HIV. When limiting the comparison to the two Alzheimer's disease participants, HIVinfected participants tended to have higher CSF IFNα but this difference was not statistically significant (p = 0.13).
In the HIV-infected participants, there was no significant difference (p = 0.94) in plasma IFNα levels between participants on cART with undetectable plasma/CSF HIV RNA (median 34.1 pg/ml, interquartile range [IQR] 3.07-98.73) and participants off cART (median 18.9 pg/ml, IQR 2.07-115.9). Similarly, CSF IFNα levels did not significantly differ (p = 0.31) between participants on cART with undetectable plasma/CSF HIV RNA (median 7.38 pg/ml, IQR 4.52-7.86) and participants off cART (median 8.34 pg/ml, IQR 6.67-16.55). There was no statistical difference (p = 0.28) in plasma IFNα among participants with either active hepatitis B or C (median 39.9 pg/ml, IQR 18.9-209.73) versus participants without (15.9 pg/ml, IQR 2.07-98.73). Similarly, there was no statistical difference (p = 0.69) in CSF IFNα levels among participants with either active hepatitis B or C (median 9.5 pg/ ml, IQR 6.67-37.38) versus participants without (median 7.86 pg/ml, IQR 4.52-12.62).
There were multiple negative correlations between CSF IFNα levels and neurocognitive performance that were statistically significant (Table 2) . CSF IFNα correlated negatively with composite NPT-8 score (r = −0.67, p = 0.006). In terms of individual NP tests, CSF IFNα correlated negatively with Trailmaking test A (r = −0.735, p = 0.0018, see Fig. 1 with 95 % density ellipse), Trailmaking test B (r = −0.677, p = 0.006), and Stroop Color-Word test (r = −0.67, p = 0.009). These three correlations remained statistically significant after false discovery rate correction (p values = 0.014, 0.022, and 0.025, respectively). There was only one significant correlation with plasma IFNα (Trailmaking test A, r = −0.561, p = 0.037), but this correlation became nonsignificant (p = 0.28) after false discovery rate correction. Pearson correlation coefficients between CSF IFNα and the identified NP performance measures remained similarly significant in the multivariable analyses adjusting for the presence of chronic hepatitis B or C (see Table 2 ). Figure 2 shows the linear regression analysis between CSF IFNα and NPT-8 (Y = 4.6564 − 0.05452X; standard deviation = 0.5581).
When comparing participants with GDS ≥0.5 versus <0.5, there was no significant difference in CSF IFNα levels (median 8.81 pg/ml .5] versus median 7.86 .05], p = 0.59) or in plasma IFNα levels (median 37 pg/ml 
Discussion
Given the high prevalence of HANDs in the cART era, there is an ongoing need to better understand the mechanisms behind these disorders. CSF levels of IFNα, an antiviral cytokine with neurotoxic properties, were found in the pre-cART era by members of our group to be significantly elevated among individuals with HIV-associated dementia (Rho et al. 1995) . However, it is unclear if this cytokine remains associated with HAND in the modern HIV treatment era, in which most affected individuals have milder forms of neurocognitive impairment. While the present study represents a small sample size, the study population was comprised of ambulatory outpatients who did not have advanced dementia. Our results show that CSF IFNα levels negatively correlate with multiple measures of neurocognitive function, including a composite score that reflects global performance. These correlations may have been driven by participants with more significant impairment (a GDS of ≥1.5 as suggested by other studies) (Cysique et al. 2015) . Participants with GDS ≥1.5 had significantly higher CSF IFNα levels. Of note, the individual tests (Trailmaking and Stroop) that were negatively associated with CSF IFNα and appeared to underpin the overall negative association with composite performance are generally regarded as tests of executive function and processing speed. These contrast with the other individual tests in our battery (which evaluated memory, fluency, and motor skill) that were not associated with CSF IFNα. Our findings suggest that the detrimental effects of IFNα may be most specific to brain regions that are linked to executive function (such as the frontal lobes and associated subcortical tracts) and processing speed (such as white matter). This is supported by the strong correlation between CSF IFNα and CSF NFL, an established marker of injury to large caliber myelinated axons in HIV and other CNS diseases (Peterson et al. 2014; Skillback et al. 2014; Zetterberg et al. 2016) .
However, we acknowledge that the mechanism of IFNα-induced neurotoxicity is not fully understood at this time (Fritz-French and Tyor 2012; Kessing and Tyor 2015) . IFNα initiates an antiviral response by binding to the type I IFN receptor (IFNAR) with subsequent activation of the JAK/ STAT pathway. However, blocking the IFNAR only partially prevents neurotoxicity caused by IFNα, suggesting that the cellular signaling involved in IFNα neurotoxicity is more complex than binding to its own receptor. The NMDA receptor (NMDAR) has also been linked to IFNα toxicity in clinical and in vitro studies (Quarantini et al. 2006) . Interestingly, other neurotoxins that have been implicated in the pathogenesis of HAND also appear to act through the NMDAR (Potter et al. 2013) . Targeting NMDAR mediated excitotoxicity may be a common pathway and further research is needed to identify HAND therapeutic candidates that would complement cART.
We acknowledge the limitations of the study, including the small sample size. We had very few HIV-seronegative controls, though previous research has shown that CSF IFNα is undetectable or near undetectable in the vast majority of healthy individuals (Abbott et al. 1987) . Two of these HIV seronegative subjects had Alzheimer's disease, and while these individuals appeared to have lower CSF IFNα levels than the HIV-infected individuals, we were not able to reject the null hypothesis that there was no statistical difference between Alzheimer's and HIV groups. It is very likely that our study was underpowered to effectively address this question. Larger studies that include more healthy HIV-seronegative individuals, more individuals with Alzeimer's disease, and more HIV-infected individuals with long-term virologic suppression on cART will be needed to determine if CSF IFNα levels are different between these groups. We also acknowledge that one third of study subjects had either chronic hepatitis B or C. Since the presence of chronic hepatitis has been shown to effect systemic interferon alpha levels (Kakumu et al. 1989) , the inclusion of these individuals may have influenced our results. However, the multivariable analysis adjusting for the presence of chronic hepatitis revealed similar negative correlations between CSF IFNα and NP performance. A larger study that excludes individuals with chronic hepatitis B/C would be needed to completely rule out the influence of hepatitis on IFNα.
While the majority of subjects in the study were cART experienced, a minority were on cART at the time of the study with suppressed plasma and CSF HIV RNA levels. While we did not find that plasma or CSF IFNα levels were lower in the individuals on cART, the sample size of subjects on cART was too small to perform a separate analysis limited to this group. Therefore, our results cannot necessarily be extrapolated to HIV-infected individuals who have achieved virologic suppression on cART. Ideally, a larger study would be performed focusing on patients with neurocognitive impairment despite virologic suppression on cART. Given the persistence of HAND in the cART era, more research is needed to better understand the relationship between IFNα and neurocognition in HIV-infected individuals. Disclaimer No financial disclosures to report.
